Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
November 25, 2020 1:18 AM 1 min read

6.4M Pfizer COVID-19 Vaccine Doses To Be Distributed Across US Within 24 Hours Of FDA Approval: WaPo

by Shivdeep Dhaliwal Benzinga Editor
Follow

Over six million doses of Pfizer Inc’s  (NYSE:PFE) COVID-19 vaccine could be distributed within 24 hours of it being given the go-ahead by the United States Food And Drug Administration, The Washington Post reported Tuesday.

What Happened: The vaccine’s 6.4 million doses would be sent across communities and the first shots are expected to be given to front-line health-care workers, according to the Post. The doses would not sufficient to cover the country’s 20 million healthcare workers.

Gustave Perna, the logistics overseer of Operation Warp Speed — the outgoing Trump administration’s program to hasten the development of COVID-19 vaccines and treatments — said the state officials were informed Friday night of allocation, which is contingent on the overall population of each state.

States are expected to designate five sites that can both receive and administer the vaccine, which must be stored at a temperature of -70 Celsius (-94 Fahrenheit), as per the Post.

Perna said a “steady drumbeat” of successive doses would be delivered weekly as manufacturing capacity picks up the pace.

Why It Matters: Priorities of first phase distribution include healthcare workers and residents of long-term care facilities, an advisory panel of the Centers for Disease Control and Prevention said, as per the Post.

Pfizer and Moderna Inc (NASDAQ:MRNA) will supply 40 million doses of their respective vaccines by the end of the year, which would be sufficient to vaccinate 20 million people, as each course of the vaccine requires two doses.

Other essential workers, people with high-risk medical conditions, and those aged over 65 would be next to receive the vaccination, according to the panel.

Price Action: Pfizer shares closed nearly 0.1% higher at $36.60 on Tuesday.

Related Link: Pfizer, BioNTech File First For Emergency Use Authorization Of Coronavirus Vaccine

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
BiotechNewsHealth CareMediaGeneralCovid-19The Washington PostVaccines
PFE Logo
PFEPfizer Inc
$27.46-0.04%
Overview
MRNA Logo
MRNAModerna Inc
$40.200.22%
PFE Logo
PFEPfizer Inc
$27.46-0.04%
Overview
MRNA Logo
MRNAModerna Inc
$40.200.22%
Comments
Loading...